Outpace Bio is a biotechnology company focused on developing treatments for solid tumors using biological approaches.

Outpace Bio

Outpace is creating cell therapies with curative potential through protein design and cellular engineering. With an initial focus on solid tumors, Outpace is developing technologies that overcome the barriers to efficacy and safety by programming cells to make the right decisions inside patients. Outpace’s suite of technologies drive persistent activity of the cell therapy (OutLast™), recruit a productive immune response in the tumor microenvironment (OutSmart™), and achieve the potency (OutSpacers™), specificity (Co-LOCKR™), and safety (EGFRopt™) necessary to unlock diverse cancer indications. Outpace’s internal and partnered pipeline approach is optimized for rapid clinical validation of its technologies across diverse cell types and manufacturing processes.

At Outpace Bio, we believe that the highest performing teams include people from a wide variety of backgrounds and experiences who respectfully challenge each other.  We are committed to building an open, diverse, and inclusive culture for all employees.

Sahsen Ventures

Abstract Ventures

Artis Ventures (AV)

Washington Research Foundation

WRF Capital

Lyell Immunopharma

Playground Global

Mubadala Capital Ventures

Civilization Ventures

Bristol-Myers Squibb

Today, we are thrilled to announce the successful closing of an oversubscribed Series B financing of $144M. This funding will propel the advancement of multiple programmed T cell product candidates to early clinical proof-of-concept in #ovariancancer and other #solidtumors, and further expand our pipeline and platform. We are also excited to welcome Jake Simson, PhD from RA Capital Management to our Board of Directors.

Our lead program, OPB-101, is a mesothelin-specific CAR T cell enhanced by Outpace's proprietary technologies: OUTSMART™, OUTLAST™, OUTSPACER™, and OUTSAFE™. OPB-101 has shown complete elimination of solid tumors in stringent in vivo models at very low treatment doses (as low as 50,000 cells) and is on track for IND clearance and first dosing in 2025 for patients with advanced platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

We extend our gratitude to our world-class syndicate of investors for believing in and supporting our mission to revolutionize treatment outcomes for #patients battling #solidtumors.

Read more in our press release: https://lnkd.in/eimM3UZi

The Series B financing brings our total capital raised to approximately $200 million and was led by RA Capital Management, with participation from new investors Qatar Investment Authority (QIA), Surveyor Capital (a Citadel company), Sheatree Capital, Black Opal Ventures, Alexandria Venture Investments (Alexandria Real Estate Equities, Inc.), and other undisclosed investors. Outpace’s existing investors ARTIS Ventures, Playground Global,  Bristol Myers Squibb Abstract Ventures, Civilization Ventures, Mubadala Capital, Breton Capital Ventures, Washington Research Foundation, Sahsen Ventures, LLC, also participated in the round.

#proteindesign #celltherapy #oncology #solidtumors #AI #biotech #syntheticbiology #seattle #CAR #TCR

#SeattleTechWeek is here and we're excited to co-host Wednesday's "Meet the Protein Designers: Happy Hour & Networking Reception" at SLU BRU alongside Monod Bio, A-Alpha Bio, Xaira Therapeutics, and Bits in Bio.

https://lu.ma/lx2bvjq3

Note: We have received overwhelming interest and the event is currently at capacity. Please update your registration if you are no longer able to join so we can welcome additional guests from the waitlist!

#proteindesign #celltherapy #AI #seattletechweek #biotech #networking #seattle

🎤  Our hometown of #Seattle is the epicenter of #AI, #proteindesign, & #celltherapy and during tomorrow's #LSINW24 #Oncology track Outpace Bio CEO & Co-founder Marc Lajoie, PhD will take the stage to share an exciting update on our latest efforts to #reprogram #cells for optimal function inside patients. Don't miss an opportunity to join our community as we come together to discuss and feature some of the most compelling #lifesciences #breakthroughs of our time at the #PacificNorthwest's largest annual life science conference: Life Science Innovation Northwest (LSINW). Learn more: https://lnkd.in/gtm893b9 #LSINW2024 #biotech #Seattle #OutpaceBio #celltherapy #AI #proteindesign #CART #TCRT #oncology #cancer

🔬 At #AACR24 we're sharing new data on the use of AI-powered protein design to program T cell therapies for unprecedented efficacy against solid tumors. Learn more: https://lnkd.in/eUAeHFqN

American Association for Cancer Research #OutpaceBio #proteindesign #AI #celltherapy #CART #CARTcells #oncology #solidtumors #cancer  #cytokines #syntheticbiology #biotech #innovation #Seattle #AACR24

🎤 Catch Outpace Bio CSO Aaron Foster on how to successfully navigate cell therapy development at today’s panel “CAR-T Therapy Journey (from Discovery to Commercialization)” at the 2024 Charles River Laboratories #CGTsummit 

#cellandgenetherapy  #advancedtherapies #cartcelltherapy #proteindesign #oncology #celltherapy

We're excited to share our latest progress in revolutionizing #celltherapy with #proteindesign at next week's #CGmesa23 meeting! Don't miss Co-founder & CEO Marc Lajoie's talk on Thursday, October 12 and the opportunity to connect with Outpacers Lindsie Goss & Eric Soller for in-person partnering. 
Alliance for Regenerative Medicine Outpace Bio 
#proteindesign #celltherapy #CART #solidtumors #AI #machinelearning

COM:OUTPACEBIO

Outpace Bio

name

homepage url

country

linkedin url

employee count

sector

industry

Description

investor of

Metrics